Circulating levels of growth hormone in postural orthostatic tachycardia syndrome
Open accessAbstract
Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder with poorly understood etiology and underlying pathophysiology. Since cardiovascular morbidity has been linked to growth hormone (GH), we studied GH levels in patients with POTS. We conducted an age-sex-matched case–control study in patients with POTS (age 31 ± 9 years; n = 42) and healthy controls (32 ± 9 years; n = 46). Plasma GH levels were measured using high-sensitivity chemiluminescence sandwich immunoassay. The burden of orthostatic intolerance symptoms was assessed by the Orthostatic Hypotension Questionnaire (OHQ), consisting of a symptom assessment scale (OHSA) and a daily activity scale (OHDAS). POTS patients had significantly higher composite OHQ score than controls, more symptoms and less activity. Supine heart rate and diastolic blood pressure (BP), but not systolic BP, were significantly higher in POTS. Median plasma GH levels were significantly lower in POTS (0.53 ng/mL) than controls (2.33 ng/mL, p = 0.04). GH levels were inversely related to OHDAS in POTS and supine systolic BP in POTS and controls, but not heart rate neither group. POTS is associated with lower GH levels. Impairment of daily life activities is inversely related with GH in POTS. A higher supine diastolic BP is inversely associated with GH levels in POTS and healthy individuals.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The daily life activities subscale (OHDAS) of the OHQ symptom burden score had a medium inverse correlation with growth hormone in POTS, where higher impairment was associated with lower levels of growth hormone.
“The daily life activities subscale (OHDAS) of the OHQ symptom burden score had a medium inverse correlation with growth hormone in POTS, where higher impairment was associated with lower levels of growth hormone.”
From Self-reported symptom burden in postural orthostatic tachycardia syndrome (POTS): A narrative review of observational and interventional studies (2023) · cites this paper as Johansson et al., 2021
The Results section (“Plasma levels of growth hormone in POTS”; page unavailable) reports that GH levels were inversely related to OHDAS scores among POTS patients (p = 0.049). The Methods section identifies OHDAS as the OHQ daily activity scale, where higher scores mean greater interference. Our copy does not report a correlation coefficient or characterize the association as medium in strength. (LLM, conf=0.86)
Experimental — accuracy not yet measuredGrowth hormone plays a role in the maintenance of the cardiovascular system, with cardiovascular morbidity being linked to both up- and down-regulation of plasma levels of growth hormone.
“Growth hormone plays a role in the maintenance of the cardiovascular system, with cardiovascular morbidity being linked to both up- and down-regulation of plasma levels of growth hormone (Johansson et al., 2021”
From Self-reported symptom burden in postural orthostatic tachycardia syndrome (POTS): A narrative review of observational and interventional studies (2023) · cites this paper as Johansson et al., 2021
People with POTS reported more orthostatic symptoms than healthy controls.
“Medium-high quality studies found that people with POTS reported more orthostatic symptoms (mean ± SD OGS score 10.54 ± 3.83 out of 20 = 52.7 %; OHQ 6.16 ± 1.78 out of 10 = 61.6 %; OIQ 16.4 ± 3.2 out of 40 = 41 %) than healthy controls (Rea et al., 2017”
From Self-reported symptom burden in postural orthostatic tachycardia syndrome (POTS): A narrative review of observational and interventional studies (2023) · cites this paper as Johansson et al., 2021
People with POTS had lower growth hormone levels than healthy controls, although levels were still within the normal range.
“This study found that people with POTS had lower growth hormone levels than healthy controls, although levels were still within the normal range.”
From Self-reported symptom burden in postural orthostatic tachycardia syndrome (POTS): A narrative review of observational and interventional studies (2023) · cites this paper as Johansson et al., 2021
The total overall OHQ symptom burden score was not significantly associated with growth hormone levels in POTS.
“The total overall OHQ symptom burden score was not significantly associated with growth hormone levels in POTS.”
From Self-reported symptom burden in postural orthostatic tachycardia syndrome (POTS): A narrative review of observational and interventional studies (2023) · cites this paper as Johansson et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cardiac origins of the postural orthostatic tachycardia syndrome
Fu, Q., VanGundy, T. B., Galbreath, M. M., Shibata, S., Jain, M., Hastings, J. L., Bhella, P. S., & Levine, B. D. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.043 · Cited by 329 · see citing works
Quality of Life in Patients With Postural Tachycardia Syndrome
Benrud-Larson, L. M., Dewar, M. S., Sandroni, P., Rummans, T. A., Haythornthwaite, J. A., & Low, P. A. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.6.531 · Cited by 217 · see citing works
Growth Hormone and Cardiovascular Risk Factors
Gola, M., Bonadonna, S., Doga, M., & Giustina, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0545 · Cited by 135 · see citing works
Postural orthostatic tachycardia syndrome: mechanisms and new therapies
Mar, P. L., & Raj, S. R. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-041818-011630 · Cited by 122 · see citing works
Regional blood volume and peripheral blood flow in postural tachycardia syndrome
Stewart, J. M., & Montgomery, L. D. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00086.2004 · Cited by 102 · see citing works
Ross, A. J., Ocon, A. J., Medow, M. S., & Stewart, J. M. (2014) · Clinical Science · doi:10.1042/cs20130222 · Cited by 78 · see citing works
Flagged first, then by citations
Research works printed but not linked: 24
- [1]Fedorowski A Postural orthostatic tachycardia syndrome: Clinical presentation, aetiology and management J. Intern. Med. 2019 285 352 366 10.1111/joim.12852 30372565 · DOI · Paper page
- [4]Hallengren E Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: The Malmo Diet and Cancer study J. Am. Coll. Cardiol. 2014 64 1452 1460 10.1016/j.jacc.2014.03.063 25277616 PMC4180127 · DOI
- [5]Lombardi G The cardiovascular system in growth hormone excess and growth hormone deficiency J. Endocrinol. Investig. 2012 35 1021 1029 10.3275/8717 23143695 · DOI
- [6]Melmed S A consensus on the diagnosis and treatment of acromegaly complications Pituitary 2013 16 294 302 10.1007/s11102-012-0420-x 22903574 PMC3730092 · DOI
- [7]Colao A Marzullo P Di Somma C Lombardi G Growth hormone and the heart Clin. Endocrinol. 2001 54 137 154 10.1046/j.1365-2265.2001.01218.x 11207626 · DOI
- [8]Medic Spahic J Proteomic analysis reveals sex-specific biomarker signature in postural orthostatic tachycardia syndrome BMC Cardiovasc. Disord. 2020 20 190 10.1186/s12872-020-01465-6 32321428 PMC7178975 · DOI
- [9]Fedorowski A Burri P Struck J Juul-Moller S Melander O Novel cardiovascular biomarkers in unexplained syncopal attacks: The SYSTEMA cohort J. Intern. Med. 2013 273 359 367 10.1111/joim.12043 23510366 · DOI · Paper page
- [10]Low PA Neurogenic orthostatic hypotension: Pathophysiology and diagnosis Am. J. Manag. Care 2015 21 s248 257 26790109
- [11]Wilkins JN Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers Psychopharmacology 1982 78 305 308 10.1007/BF00433730 6818588 · DOI
- [12]Jansz A Doorenbos H Reitsma WD Effect of food intake on growth-hormone level Lancet 1963 1 250 251 10.1016/s0140-6736(63)90957-7 13957442 · DOI
- [13]Bidlingmaier M High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports Clin. Chem. 2009 55 445 453 10.1373/clinchem.2008.112458 19168559 · DOI
- [14]Bagai K Sleep disturbances and diminished quality of life in postural tachycardia syndrome J. Clin. Sleep Med. 2011 7 204 210 10.5664/jcsm.28110 21509337 PMC3077350 · DOI · Paper page
- [16]Brod M Pohlman B Hojbjerre L Adalsteinsson JE Rasmussen MH Impact of adult growth hormone deficiency on daily functioning and well-being BMC Res. Notes 2014 7 813 10.1186/1756-0500-7-813 25406443 PMC4255661 · DOI
- [18]Gazzaruso C Gola M Karamouzis I Giubbini R Giustina A Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH–an update J. Clin. Endocrinol. Metab. 2014 99 18 29 10.1210/jc.2013-2394 24217903 · DOI
- [19]Diez JJ Sangiao-Alvarellos S Cordido F Treatment with growth hormone for adults with growth hormone deficiency syndrome: Benefits and risks Int. J. Mol. Sci. 2018 10.3390/ijms19030893 29562611 PMC5877754 · DOI
- [20]Cordoba-Chacon J Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP J. Neuroendocrinol. 2012 24 453 463 10.1111/j.1365-2826.2011.02261.x 22129035 · DOI
- [21]Sverrisdottir YB Elam M Herlitz H Bengtsson BA Johannsson G Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency J. Clin. Endocrinol. Metab. 1998 83 1881 1885 10.1210/jcem.83.6.4895 9626113 · DOI
- [23]Casanueva FF Villanueva L Cabranes JA Cabezas-Cerrato J Fernandez-Cruz A Cholinergic mediation of growth hormone secretion elicited by arginine, clonidine, and physical exercise in man J. Clin. Endocrinol. Metab. 1984 59 526 530 10.1210/jcem-59-3-526 6746865 · DOI
- [25]Blitshteyn S Fries D Postural tachycardia syndrome is not caused by deconditioning Pulm. Circ. 2016 6 401 10.1086/687757 27683618 PMC5019095 · DOI
- [26]Isgaard J Cittadini A Growth hormone and the heart in growth hormone deficiency-what have we learned so far? Endocrine 2017 55 331 332 10.1007/s12020-016-1206-0 27981513 · DOI
- [27]Thomas SG Esposito JG Ezzat S Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment J. Clin. Endocrinol. Metab. 2003 88 5734 5738 10.1210/jc.2003-030632 14671161 · DOI
- [28]Kim SH Park MJ Effects of growth hormone on glucose metabolism and insulin resistance in human Ann. Pediatr. Endocrinol. Metab. 2017 22 145 152 10.6065/apem.2017.22.3.145 29025199 PMC5642081 · DOI · Paper page
- [29]Yuen KC Dunger DB Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults Diabetes Obes. Metab. 2007 9 11 22 10.1111/j.1463-1326.2006.00591.x 17199714 · DOI
- [30]Barreto-Filho JA Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia J. Clin. Endocrinol. Metab. 2002 87 2018 2023 10.1210/jcem.87.5.8474 11994335 · DOI
Cited by
Sorted by citations
Knoop, I., Picariello, F., Jenkinson, E., Gall, N., Chisari, C., & Moss-Morris, R. (2023) · Autonomic Neuroscience · doi:10.1016/j.autneu.2022.103052 · Cited by 21 · see citing works
“Mean ± SD 6 ± 4 155 Score / 10 OHQ total Number of participants POTS Johansson et al., 2021.”
- Authors
- Johansson, M., Ricci, F., Schulte, J., Persson, M., Melander, O., Sutton, R., Hamrefors, V., & Fedorowski, A.
- Affiliations
- Lund University (SE)
- SphingoTec GmbH (Germany) (DE)
- Corresponding author
- Johansson, Madeleine
- ORCID
- Venue
- Scientific Reports
- Published
- 2021-04-21
- Volume
- 11
- Issue
- 1
- Pages
- 8575-8575
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8060383
- OpenAlex
- W3155186184
- Cited by
- 9
- References
- 6
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- Crafoordska Stiftelsen (20190006)
- Hjärt-Lungfonden (20190383)
- Eva and Carl-Eric Larsson Foundation (2019001)
- Lund University
- Topics
- Health Sciences › Medicine › Surgery › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- postural orthostatic tachycardia syndrome, growth hormone, plasma growth hormone, orthostatic intolerance, cardiac autonomic dysfunction, diastolic blood pressure, heart rate, activity impairment
- MeSH terms
- Adolescent, Adult, Humans, Male, Middle Aged, Surveys and Questionnaires, Case-Control Studies, Human Growth Hormone, Postural Orthostatic Tachycardia Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
